MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.

By Valerie B. Sampson, N. H. Rong, Jian Han, Qunying Yang, Virginie Aris, P. Soteropoulos, N. Petrelli, S. Dunn, L. Krueger. Cancer Research, 2007

833 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/bda0f05562211b64c7e0968e83710d93eadad7bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pathology and Forensic Medicine

Carlo Maria Croce

Citations in the corpus

Non‐coding RNAs: regulators of disease (2010, background): “Completing the feedback loop, let-7 targets LIN28 [75,80,81], c-Myc [82,83] and the c-Myc-activating gene IMP-1 [80].”
TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. (2009, background): “By targeting multiple oncogenes such as RAS, HMGA2, and c-MYC, let-7 also functions as a tumor suppressor, most prominently in lung cancer (Johnson et al., 2005; Lee and Dutta, 2007; Mayr et al., 2007; Sampson et al., 2007).”
The mammalian ovary from genesis to revelation. (2009, background): “BRCA1 binds MYC and represses its tran- scriptional and transforming activity (229).”
c-Myc and Cancer Metabolism (2012, positive): “hand, overexpression of the let-7a miRNA causes dramatic decreases in c-Myc gene expression and its target genes, as well as antiproliferative activity in lymphoma cells (21).”
MicroRNAs in cancer: small molecules with a huge impact. (2009, background): “elegans, where it induces cell cycle exit and terminal differentiation, has been described as a new regulator of self-renewal and tumorigenicity of breast cancer cells,(59) targeting molecules originally described in lung cancer: RAS(29) as well as the oncogene HMGA2,(29,30) and even MYC itself.(31)”
An epigenetic switch involving NF-κB, Lin28, let-7 microRNA, and IL6 links inflammation to cell transformation (2009, positive): “Activation of the NF-kB pathway is correlated with carcinogenesis (Luo et al., 2005), Let-7 is downregulated in several cancers (Johnson et al., 2005; Mayr et al., 2007; Sampson et al., 2007 ), Lin28 is overexpressed in primary human tumors (Viswanathan et al., 2009)(Figure 7D),and IL6has been impl”
MicroRNAs in development and disease. (2011, background): “Whereas let-7 is known for its tumor suppressive function via targeting c-myc in lymphoma cells (526), miR-223 has been shown to increase during granulocyte differentiation (281) and is sufficient for inducing differentiation of myeloid leukemia cells when ectopically expressed (172).”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “…cancer pathways, such BCL2 (targeted by miR-15a–miR-16-1; Cimmino et al, 2005), RAS (regulated by let-7; Johnson et al, 2005), myeloid cell leukaemia sequence 1 (BCl-2-related, MCL1, and targeted by miR-29; Garzon et al, 2009; Mott et al, 2007) and MYC (targeted by let-7; Sampson et al, 2007).”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, neutral): “…and Dutta (2007); Lu et al. (2007a); Mayr et al. (2007); Meng et al. (2007b); Park et al. (2007); Pasquinelli et al. (2000); Reinhart et al. (2000); Sampson et al. (2007); Shell et al. (2007); Yanaihara et al. (2006) miR-1 Involved in cardiogenic and myogenic differentiation; involved in…”
MicroRNAs and cancer: short RNAs go a long way. (2009, background): “Functionally, let-7 represses members of the Ras family of oncogenes (Johnson et al., 2005) as well as the oncogene HMGA2 (Lee and Dutta, 2007; Mayr et al., 2007) and even c-Myc itself (Sampson et al., 2007).”